Bronte Capital Management Pty Ltd. Vir Biotechnology, Inc. Transaction History
Bronte Capital Management Pty Ltd.
- $1.12 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding VIR
# of Institutions
218Shares Held
87MCall Options Held
127KPut Options Held
1.19M-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$123 Million1.03% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$122 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$97.2 Million0.0% of portfolio
-
State Street Corp Boston, MA5.63MShares$41.6 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.57MShares$26.4 Million0.63% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $982M
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...